Lifeboat Foundation

## JOURNAL OF THE AMERICAN CHEMICAL SOCIETY • JUN 4, 2021.

# *A lovely single step bio-inspired process with some interesting complex benefits particularly for humans on Mars.*

*by holly ober, university of california — riverside*

Continue reading “A catalyst that destroys perchlorate in water could clean Martian soil” »

It’s not just corporations that are facing an epidemic of cyber attacks — American retail investors are also struggling to contend with a surge in hackers taking over their investment accounts, regulators warn.

Automation could aid biodiversity monitoring.

Banner Smoked Fish Inc. is recalling 43 of its s moked fish products in all package sizes, all package types and all lots, because of a potential Listeria monocytogenes contamination.

The problem was discovered through FDA routine inspection, and the products were found to be processed under unsanitary condition.

The recalled smoked fish were distributed through retail stores and also online in the New York, New Jersey, Illinois, Pennsylvania, California, Florida, Nebraska, Arizona, Massachusetts, Maryland, Virginia, Nevada, Oregon, Wisconsin, North Carolina, South Carolina and Georgia.

Antivirus software company Norton has released a new crypto product that allows users to mine ether (ETH) from their personal computers.

NortonLifeLock, formerly Symantec Corporation, has released a new crypto product that allows users to mine ether (ETH) from their personal computers.

The product, Norton Crypto, is currently available to select customers who use the company’s antivirus software called Norton 360. The public launch of the product is expected “in the coming weeks.”

Continue reading “Antivirus software company Norton now allows mining ETH via pool service” »

Enrolling Tens Of Thousands Of Dogs, In 10-Year Study, To Unlock Healthy Aging Secrets — Dr Matt Kaeberlein, Founder / Co-Director, The Dog Aging Project, Professor, University of Washington, joins me on Progress, Potential, And Possibilities Nathan Shock Centers #Rapamycin #Dogs #Aging #Longevity #Healthspan #Geroscience.

#MitochondrialDisease

Continue reading “Dr. Matt Kaeberlein — Founder / Co-Director, Dog Aging Project — Professor, University of Washington” »

If space moguls like Elon Musk have their way, the red planet could one day be home to millions of people.

Arcadia Planitia, located in the northern hemisphere of the red planet, holds promise as a habitable, resource-rich area for space civilizations.

The latest from Calico. A bit technical.

Reprogramming of ordinary somatic cells into induced pluripotent stem cells (iPSCs) was initially thought to be a way to obtain all of the patient matched cells needed for tissue engineering or cell therapies. A great deal of work has gone towards realizing that goal over the past fifteen years or so; the research community isn’t there yet, but meaningful progress has taken place. Of late, another line of work has emerged, in that it might be possible to use partial reprogramming as a basis for therapy, delivering reprogramming factors into animals and humans in order to improve tissue function, without turning large numbers of somatic cells into iPSCs and thus risking cancer or loss of tissue structure and function.

Reprogramming triggers some of the same mechanisms of rejuvenation that operate in the developing embryo, removing epigenetic marks characteristic of aged tissues, and restoring youthful mitochondrial function. It cannot do much for forms of damage such as mutations to nuclear DNA or buildup of resilient metabolic waste, but the present feeling is there is nonetheless enough of a potential benefit to make it worth developing this approach to treatments for aging. Some groups have shown that partial reprogramming — via transient expression of reprogramming factors — can reverse functional losses in cells from aged tissues without making those cells lose their differentiated type. But this is a complicated business. Tissues are made up of many cell types, all of which can need subtly different approaches to safe reprogramming.

Today’s open access preprint is illustrative of the amount of work that lies ahead when it comes to the exploration of in vivo reprogramming. Different cell types behave quite differently, will require different recipes and approaches to reprogramming, different times of exposure, and so forth. It makes it very hard to envisage a near term therapy that operates much like present day gene therapies, meaning one vector and one cargo, as most tissues are comprised of many different cell types all mixed in together. On the other hand, the evidence to date, including that in the paper here, suggests that there are ways to create the desired rejuvenation of epigenetic patterns and mitochondrial function without the risk of somatic cells dedifferentiating into stem cells.

Continue reading “A Great Deal of Work Lies Ahead in the Development of In Vivo Reprogramming as a Therapy” »

Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S.

The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide, for long-term weight management.

In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms). Participants lost weight steadily for 16 months before plateauing. In a comparison group getting dummy shots, the average weight loss was about 2.5%, or just under 6 pounds.